Immunosuppressive properties of mesenchymal stromal cells derived from amnion, placenta, Wharton's jelly and umbilical cord
Immunosuppressive properties of mesenchymal stromal cells derived from amnion, placenta, Wharton's jelly and umbilical cord
复制标题
DOI：
10.1111/imj.12044
复制
发表时间：
2013-04-01
影响因子：
2.1
通讯作者：
Issaragrisil, S.
中科院分区：
文献类型：
--
作者：
Manochantr, S.;U-Pratya, Y.;Issaragrisil, S.
背景最近报道了骨髓间充质基质细胞（BM-MSC）在预防移植物抗宿主病（GvHD）的发生和改善其严重程度方面的作用。然而，由于 BM-MSC 的采集是一种侵入性操作，因此需要更容易获得的 MSC 来源。目的本研究旨在探索羊膜、胎盘、沃顿胶和脐带等通常被丢弃的间充质干细胞的替代来源。方法通过机械解离和酶消化从这些组织中分离MSC。研究了它们的增殖和分化能力以及抑制同种异体反应性 T 淋巴细胞的能力，并与 BM-MSC 进行了比较。结果羊膜、胎盘、沃顿胶和脐带来源的MSC在细胞形态、免疫表型以及分化能力方面与BM-MSC相似。与 BM-MSC 相比，这些 MSC 还引发了类似程度的免疫抑制，这一点可以通过混合淋巴细胞反应中同种异体反应性 T 淋巴细胞的抑制来证明。与BM-MSC相比，来自脐带和沃顿胶的MSC具有较高的增殖能力，而来自羊膜和胎盘的MSC具有较低的增殖能力。结论 本研究获得的结果表明，来自羊膜、胎盘、沃顿胶和脐带的 MSC 有可能在多种治疗应用中替代 BM-MSC，包括治疗 GvHD。
Background The role of bone marrow-derived mesenchymal stromal cells (BM-MSC) in preventing the incidence and ameliorating the severity of graft-versus-host disease (GvHD) has recently been reported. However, as the collection of BM-MSC is an invasive procedure, more accessible sources of MSC are desirable. Aim This study aimed to explore the alternative sources of MSC from amnion, placenta, Wharton's jelly and umbilical cord, which are usually discarded. Methods MSC from those tissues were isolated using mechanical dissociation and enzymatic digestion. Their capacity for proliferation and differentiation, and ability to suppress alloreactive T-lymphocytes were studied and compared with those of BM-MSC. Results MSC derived from amnion, placenta, Wharton's jelly and umbilical cord were similar to BM-MSC regarding the cell morphology, the immunophenotype as well as the differentiation ability. These MSC also elicited a similar degree of immunosuppression, as evidenced by the inhibition of alloreactive T-lymphocytes in the mixed lymphocyte reaction, compared with that of BM-MSC. MSC from umbilical cord and Wharton's jelly had a higher proliferative capacity, whereas those from amnion and placenta had a lower proliferative capacity compared with BM-MSC. Conclusion The results obtained from this study suggest that MSC from amnion, placenta, Wharton's jelly and umbilical cord can therefore be potentially used for substituting BM-MSC in several therapeutic applications, including the treatment of GvHD.